Mesna Altan

Mesna, the active ingredient in Mesna Altan, is a uroprotective agent presented as an intravenous solution for intravenous use. It binds and inactivates the toxic metabolite acrolein, thereby preventing hemorrhagic cystitis in adult and pediatric patients receiving cyclophosphamide or ifosfamide chemotherapy.

GNH USA supplies Mesna Altan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, providing reliable cold‑chain logistics, regulatory compliance and comprehensive quality assurance for all shipments.

Mesna is used as an adjunct in chemotherapy regimens to protect the urinary tract.

- Cyclophosphamide therapy: prevents hemorrhagic cystitis in patients receiving cyclophosphamide. - Ifosfamide therapy: prevents hemorrhagic cystitis in patients receiving ifosfamide. - High‑dose chemotherapy protocols: reduces the risk of bladder toxicity during intensive treatment courses.

Mesna may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Vomiting: occasional emesis. - Headache: transient headache. - Metallic taste: altered taste sensation. - Flushing: mild skin flushing.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction. - Hemolysis: rare red blood cell destruction. - Severe hypotension: sudden drop in blood pressure. - Pulmonary edema: fluid accumulation in the lungs.

When using Mesna, clinicians should observe several safety measures.

- Renal function: assess kidney function before administration. - Concomitant nephrotoxic drugs: avoid or closely monitor use with other nephrotoxic agents. - Electrolyte balance: monitor serum electrolytes, especially potassium. - Fluid status: ensure adequate hydration to reduce bladder toxicity. - Pregnancy and lactation: use only if benefits outweigh risks; data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mesna can interact with other medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Nitrofurantoin: concurrent use may reduce the protective effect of mesna. - High‑dose vitamin C: may interfere with mesna’s sulfhydryl activity.

Moderate Interactions (Monitor Closely): - Other nephrotoxic agents (e.g., aminoglycosides): monitor renal function. - Loop diuretics: may affect fluid balance and urinary concentration. - Anticoagulants: observe for altered bleeding risk due to possible renal changes.